News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Exelixis, Inc. Says Quickly Filled Spots in Cancer Trial
January 11, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
SAN FRANCISCO, Jan 10 (Reuters) - Exelixis Inc (EXEL.O: Quote, Profile, Research) said it quickly attracted patients with non-small cell lung cancer for a trial of its experimental cancer drug XL647, Chief Executive George Scangos said on Thursday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Exelixis, Inc.
MORE ON THIS TOPIC
Alzheimer’s
Prothena’s Alzheimer’s Drug Comes With Familiar Side Effect in Phase I Test
August 28, 2025
·
2 min read
·
Annalee Armstrong
IN PARTNERSHIP WITH TRUVETA
Webinar: AI for Faster, More Precise Real-World Research: Extracting Clinical Notes Data at Scale
August 27, 2025
·
1 min read
·
BioSpace Insights
Regulatory
The US Is Losing Its Biopharma Edge, Writes Former FDA Commissioner
August 27, 2025
·
3 min read
·
Dan Samorodnitsky
Rare diseases
Regeneron Eyes 2026 Filing for siRNA Myasthenia Gravis Drug After Phase III Win
August 27, 2025
·
2 min read
·
Tristan Manalac
